Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
CMChemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. (CMMB)

NASDAQ Capital Market · Currency in USD
$1.03 ▼ -0.05 (-4.63%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.04 ▲ +0.01 (+0.97%)
After hours: Oct 23, 6:17 PM ET

Summary

Previous Close
$1.08
Open
$1.10
Day's Range
$1.03 – $1.21
52 Week Range
$1.01 – $3.44
Volume
25,085
Avg. Volume
141,217
Market Cap
$6.34M
Beta (5Y Monthly)
0.66
PE Ratio (TTM)
--
EPS (TTM)
-$0.95
Earnings Date
Nov 6, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Chemomab Therapeutics Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
12
CEO
Adi Mor George

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Earnings

Next report: Fri, Nov 6, 2026
EPS estimate -$0.01
DateEst.Actual
Aug 19, 2026-$0.15-$0.27Miss
May 14, 2026-$0.04-$0.22Miss
Mar 19, 2026-$0.20-$0.24Miss
Nov 13, 2025-$0.20-$0.02Beat
Aug 14, 2025-$0.20-$0.36Miss
May 15, 2025-$0.20-$0.56Miss

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on CMMB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.